Research

Funding from the state Department of Health is enabling the center to expand care to families experiencing dementia in all 8 WNY counties.

Robert Zivadinov, MD, PhD, professor of neurology and biomedical informatics in the Jacobs School of Medicine and Biomedical Sciences, has been named a SUNY Distinguished Professor, the highest rank in the SUNY system.

Imagine waking up one day and finding that you are suddenly having difficulty swallowing, walking and talking. You start experiencing involuntary muscle contractions called dystonias. Then imagine that these symptoms do not go away.

Brain lesions — areas of brain tissue that show damage from injury or disease — are the biomarker most widely used to determine multiple sclerosis disease progression. But an innovative new study led by the University at Buffalo strongly suggests that the volume of white matter lesions is neither proportional to, nor indicative of, the degree of severe disability in patients. 

Researchers at the University at Buffalo are hard at work studying rare diseases and caring for the many patients suffering from them. UB will hold an event recognizing rare disease patients, their clinicians and the researchers working to discover causes — and ultimately cures — for these conditions.

University at Buffalo faculty members Stelios Andreadis, PhD, and M. Laura Feltri, MD, have been elected fellows of the American Association for the Advancement of Science (AAAS), the world’s largest general scientific society and publisher of the Science family of journals.

From the time she heard about the inaugural Graduate Student Research Day, Taylor Wicks was thrilled with the opportunity to showcase her work.

Adults experiencing long COVID may be interested in a new University at Buffalo clinical trial that is testing low-dose lithium as a potential treatment.

Gil I. Wolfe, MD, UB Distinguished Professor and the Irvin and Rosemary Smith Chair of the Department of Neurology, is involved in trials of FcRn (neonatal FC receptor) antagonists that offers a new approach to treating myasthenia gravis (MG).